公司LinX持续葡萄糖监测系统在巴西获批上市，将极大强化公司在拉丁美洲的市场布局，为国际业务 的规模化扩张与收入增长奠定坚实基础。未来，公司将继续聚焦糖尿病监测、治疗及管理方式的全球发 展，持续推动相关领域技术与产品创新。 微泰医疗-B(02235)公布，集团的的LinX持续葡萄糖监测系统，近期获得巴西的上市批准，适用于成人 及儿童的连续动态血糖监测。 ...

Core Viewpoint - 微泰医疗-B's LinX continuous glucose monitoring system has received market approval in India, marking a significant entry into a high-growth market with substantial diabetes management needs [1] Company Summary - The LinX system is recognized for its superior performance and reliability, having been integrated into healthcare systems across multiple European countries and gaining access in emerging markets in the Middle East, Asia-Pacific, and South America [1] - The approval in India is expected to greatly expand the company's international market reach, laying a solid foundation for scaling international operations and revenue growth [1] Industry Summary - The global continuous glucose monitoring market is experiencing strong growth, with India representing a core emerging market with vast potential [1] - According to the IDF's 2025 Global Diabetes Map, there are approximately 89.83 million diabetes patients aged 20-79 in India, with a prevalence rate of 9.5%, ranking second globally [1] - The rising prevalence of prediabetes and the trend of younger patients indicate a significant gap in diabetes management systems, creating urgent demand for digital and intelligent diabetes management solutions [1] - The company's focus on global development in diabetes monitoring, treatment, and management will continue to drive innovation in related technologies and products [1]

Core Viewpoint - The company has received approval for its LinX continuous glucose monitoring system in India, marking a significant entry into a high-growth market with substantial diabetes prevalence [1]. Group 1: Product Approval and Market Entry - The LinX system has been approved for continuous glucose monitoring in adults in India, enhancing the company's international market presence [1]. - The system has already been integrated into healthcare systems across multiple European countries and has gained access in emerging markets in the Middle East, Asia-Pacific, and South America [1]. Group 2: Market Potential and Demand - India has approximately 89.83 million diabetes patients aged 20-79, with a prevalence rate of 9.5%, ranking second globally [1]. - The country also has the highest number of diabetes-related deaths, indicating a critical need for effective diabetes management solutions [1]. - The rising prevalence of prediabetes and the trend of younger patients highlight a significant gap in the current healthcare system, creating urgent demand for digital and intelligent diabetes management solutions [1]. Group 3: Future Focus - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management, driving innovation in related technologies and products [2].